Evidence map›Paper›PMID 36171879›Full record

ArticleFrontiers in genetics2022

Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.

Zhengjun Lin, Yanlin Wu, XunGang Xiao, Xianghong Zhang, Jia Wan, Tao Zheng, Hongxuan Chen, Tang Liu, Xianzhe Tang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zhengjun LinDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yanlin WuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
XunGang XiaoDepartment of Orthopedics, Chenzhou No. 1 People's Hospital, Chenzhou, Hunan, China.
Xianghong ZhangDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jia WanDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Tao ZhengDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hongxuan ChenDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Tang LiuDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xianzhe TangDepartment of Orthopedics, Chenzhou No. 1 People's Hospital, Chenzhou, Hunan, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNChenzhou First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CREB3L1drug sensitivityimmunotherapy efficacypan-cancerprognostic biomarkertumor immune microenvironment

Identifiers

PMID36171879
PMCPMC9511413
OpenAlexW4295181181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.